{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "binds",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02137",
      "entity_text" : "KIR-L",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P55040",
      "entity_text" : "KIR",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0649" ],
      "Cellular_component" : [ "uniprot:SL-0487" ],
      "CellType" : [ "cl:CL:0000623" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "Thus, Lirilumab, a first-in-class humanized IgG4 mAb directed against a common epitope shared by KIR2D, disrupts the KIR / KIR-L interaction by rendering NK cells \" alloreactive \" and allows killing of tumor target cells.",
  "reading_complete" : "2020-08-04T11:10:34Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T11:05:52Z",
  "trigger" : "interaction",
  "evidence" : [ "KIR/KIR-L interaction" ],
  "pmc_id" : "6558367",
  "score" : 0
}